CMC
Neutral signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Supports a bullish reading. Current ratio 2.78 · operating margin 6.7%
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
ACHAT TOTAL: 9 620 titres (~604 467,80 $ US)
- Insiders
- McPherson John RMATT PETER R
- Total bought
-
$604,468
Avg buy (VWAP, 90d window) $62.83 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
- Last activity
- 2026-08-13
- Last synced
-
2026-08-21 23:36:53
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-13 | McPherson John R | Buy | 1,390 | $71.92 | $99,969 | Form 4 |
| 2026-07-10 | MATT PETER R | Buy | 8,230 | $61.30 | $504,499 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Neutral signalScored 2026-08-16
CMC presents a genuine event-driven catalyst — insider cluster buys, a $600M buyback expansion, and an ambitious $1.8B EBITDA target signal management conviction in a near-term turnaround, supported by institutional…
The first sentence of the analysis written for CMC on 2026-08-16 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 | 2021-08-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 15.6% | 17.1% | 20.6% | 20.8% | 16.4% | |
| Ebit Margin | 2.0% | 8.6% | 13.2% | 17.6% | 8.7% | |
| Ebitda Margin | 5.6% | 12.2% | 15.7% | 19.5% | 11.2% | |
| Operating Profit Margin | 6.7% | 8.8% | 13.3% | 14.7% | 8.9% | |
| Pretax Profit Margin | 1.4% | 8.0% | 12.8% | 17.0% | 7.9% | |
| Continuous Operations Profit Margin | 1.1% | 6.1% | 9.8% | 13.7% | 6.1% | |
| Net Profit Margin | 1.1% | 6.1% | 9.8% | 13.7% | 6.1% | |
| Bottom Line Profit Margin | 1.1% | 6.1% | 9.8% | 13.7% | 6.1% | |
| Current Ratio | 2.776 | 3.944 | 3.727 | 2.536 | 2.791 | |
| Quick Ratio | 2.034 | 2.780 | 2.499 | 1.674 | 1.837 | |
| Solvency Ratio | 0.124 | 0.304 | 0.428 | 0.472 | 0.248 | |
| Cash Ratio | 0.829 | 1.028 | 0.702 | 0.496 | 0.508 | |
| Price To Earnings Ratio | 76.893 | 12.790 | 7.669 | 4.015 | 9.510 | |
| Price To Earnings Growth Ratio | -0.937 | -0.298 | -0.281 | 0.021 | 0.207 | |
| Forward Price To Earnings Growth Ratio | -0.937 | -0.298 | -0.281 | 0.021 | 0.207 | |
| Price To Earnings Diluted Ratio | 77.932 | 12.944 | 7.764 | 4.071 | 9.651 | |
| Price To Earnings Diluted Growth Ratio | -0.949 | -0.302 | -0.286 | 0.021 | 0.211 | |
| Price To Book Ratio | 1.554 | 1.444 | 1.599 | 1.487 | 1.711 | |
| Price To Sales Ratio | 0.836 | 0.783 | 0.749 | 0.548 | 0.583 | |
| Price To Free Cash Flow Ratio | 20.869 | 10.789 | 8.937 | 19.525 | 88.592 | |
| Price To Operating Cash Flow Ratio | 9.113 | 6.900 | 4.903 | 6.979 | 17.181 | |
| Debt To Assets Ratio | 0.189 | 0.174 | 0.174 | 0.241 | 0.231 | |
| Debt To Equity Ratio | 0.323 | 0.277 | 0.280 | 0.457 | 0.466 | |
| Debt To Capital Ratio | 0.244 | 0.217 | 0.219 | 0.314 | 0.318 | |
| Long Term Debt To Capital Ratio | 0.238 | 0.211 | 0.213 | 0.253 | 0.307 | |
| Financial Leverage Ratio | 1.710 | 1.586 | 1.611 | 1.898 | 2.021 | |
| Working Capital Turnover Ratio | 3.323 | 3.331 | 4.014 | 4.641 | 4.173 | |
| Operating Cash Flow Ratio | 0.568 | 1.078 | 1.593 | 0.516 | 0.233 | |
| Operating Cash Flow Sales Ratio | 0.092 | 0.114 | 0.153 | 0.079 | 0.034 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.437 | 0.640 | 0.549 | 0.357 | 0.194 | |
| Debt Service Coverage Ratio | 4.634 | 9.388 | 13.873 | 3.283 | 5.951 | |
| Interest Coverage Ratio | 11.427 | 14.482 | 29.117 | 25.862 | 11.574 | |
| Short Term Operating Cash Flow Coverage Ratio | 16.146 | 23.197 | 33.177 | 1.801 | 4.203 | |
| Operating Cash Flow Coverage Ratio | 0.528 | 0.756 | 1.164 | 0.466 | 0.214 | |
| Capital Expenditure Coverage Ratio | 1.775 | 2.775 | 2.216 | 1.556 | 1.241 | |
| Dividend Paid And Capex Coverage Ratio | 1.477 | 2.232 | 1.972 | 1.353 | 0.944 | |
| Dividend Payout Ratio | 0.962 | 0.162 | 0.087 | 0.056 | 0.140 | |
| Enterprise Value Multiple | 15.555 | 6.785 | 5.180 | 3.284 | 5.968 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 15.7% | ▼-1.5% | ▼-2.5% |
| Ebit Margin | 2.0% | ▼-6.7% | ▼-8.1% |
| Ebitda Margin | 5.6% | ▼-6.5% | ▼-7.2% |
| Operating Profit Margin | 6.7% | ▼-2.1% | ▼-3.8% |
| Pretax Profit Margin | 1.4% | ▼-6.6% | ▼-8.0% |
| Continuous Operations Profit Margin | 1.1% | ▼-5.0% | ▼-6.3% |
| Net Profit Margin | 1.1% | ▼-5.0% | ▼-6.3% |
| Bottom Line Profit Margin | 1.1% | ▼-5.0% | ▼-6.3% |
| Current Ratio | 2.776 | ▼-1.168 | ▼-0.379 |
| Quick Ratio | 2.034 | ▼-0.746 | ▼-0.131 |
| Solvency Ratio | 0.124 | ▼-0.180 | ▼-0.191 |
| Cash Ratio | 0.829 | ▼-0.199 | ▲0.116 |
| Price To Earnings Ratio | 76.893 | ▲64.103 | ▲54.718 |
| Price To Earnings Growth Ratio | -0.937 | ▼-0.639 | ▼-0.679 |
| Forward Price To Earnings Growth Ratio | -0.937 | ▼-0.639 | ▼-0.679 |
| Price To Earnings Diluted Ratio | 77.932 | ▲64.988 | ▲55.460 |
| Price To Earnings Diluted Growth Ratio | -0.949 | ▼-0.647 | ▼-0.688 |
| Price To Book Ratio | 1.554 | ▲0.110 | ▼-0.005 |
| Price To Sales Ratio | 0.836 | ▲0.052 | ▲0.136 |
| Price To Free Cash Flow Ratio | 20.869 | ▲10.081 | ▼-8.873 |
| Price To Operating Cash Flow Ratio | 9.113 | ▲2.213 | ▲0.098 |
| Debt To Assets Ratio | 0.189 | ▲0.014 | ▼-0.013 |
| Debt To Equity Ratio | 0.323 | ▲0.046 | ▼-0.038 |
| Debt To Capital Ratio | 0.244 | ▲0.027 | ▼-0.018 |
| Long Term Debt To Capital Ratio | 0.238 | ▲0.027 | ▼-0.006 |
| Financial Leverage Ratio | 1.710 | ▲0.125 | ▼-0.055 |
| Working Capital Turnover Ratio | 3.323 | ▼-0.009 | ▼-0.574 |
| Operating Cash Flow Ratio | 0.568 | ▼-0.510 | ▼-0.230 |
| Operating Cash Flow Sales Ratio | 0.092 | ▼-0.022 | ▼-0.002 |
| Free Cash Flow Operating Cash Flow Ratio | 0.437 | ▼-0.203 | ▲0.001 |
| Debt Service Coverage Ratio | 4.634 | ▼-4.755 | ▼-2.792 |
| Interest Coverage Ratio | 11.427 | ▼-3.055 | ▼-7.065 |
| Short Term Operating Cash Flow Coverage Ratio | 16.145 | ▼-7.051 | ▲0.441 |
| Operating Cash Flow Coverage Ratio | 0.528 | ▼-0.228 | ▼-0.098 |
| Capital Expenditure Coverage Ratio | 1.775 | ▼-0.999 | ▼-0.137 |
| Dividend Paid And Capex Coverage Ratio | 1.477 | ▼-0.755 | ▼-0.119 |
| Dividend Payout Ratio | 0.962 | ▲0.799 | ▲0.680 |
| Enterprise Value Multiple | 15.555 | ▲8.771 | ▲8.201 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $6.52B | $6.21B | $6.59B | $4.89B | $3.93B | |
| Enterprise value | $6.83B | $6.54B | $7.15B | $5.72B | $4.50B | |
| EV / Sales | 0.88x | 0.82x | 0.81x | 0.64x | 0.67x | |
| EV / Op. cash flow | 9.55x | 7.27x | 5.32x | 8.16x | 19.68x | |
| EV / Free cash flow | 21.86x | 11.37x | 9.70x | 22.84x | 101.50x | |
| EV / EBITDA | 15.55x | 6.79x | 5.18x | 3.28x | 5.97x | |
| Net debt / EBITDA | 0.71x | 0.34x | 0.41x | 0.48x | 0.76x | |
| Current ratio | 2.78x | 3.94x | 3.73x | 2.54x | 2.79x | |
| Income quality | 8.45x | 1.85x | 1.56x | 0.57x | 0.55x | |
| Graham number | $25 | $59 | $76 | $79 | $38 | |
| Graham net-net | -$5 | -$3 | -$4 | -$6 | -$5 | |
| Tax burden | 78.7% | 76.4% | 76.6% | 80.3% | 77.3% | |
| Interest burden | 70.3% | 93.0% | 96.5% | 96.8% | 91.1% | |
| Working capital | $2.24B | $2.46B | $2.30B | $2.08B | $1.76B | |
| Invested capital | $5.58B | $5.66B | $5.35B | $4.50B | $3.40B | |
| Return on assets | 1.2% | 7.1% | 12.9% | 19.5% | 8.9% | |
| Operating ROA | 7.4% | 10.3% | 18.1% | 24.1% | 13.8% | |
| Return on tangible assets | 1.3% | 7.8% | 14.3% | 21.2% | 9.0% | |
| Return on equity | 2.0% | 11.3% | 20.9% | 37.0% | 18.0% | |
| Return on invested capital | 6.9% | 8.8% | 15.3% | 20.0% | 12.5% | |
| Return on capital employed | 8.8% | 11.6% | 20.2% | 26.9% | 16.4% | |
| Earnings yield | 1.3% | 7.8% | 13.0% | 24.9% | 10.5% | |
| Free cash flow yield | 4.8% | 9.3% | 11.2% | 5.1% | 1.1% | |
| Capex / Op. cash flow | 56.3% | 36.0% | 45.1% | 64.3% | 80.6% | |
| Capex / Depreciation | 140.9% | 115.7% | 277.2% | 257.1% | 109.9% | |
| Capex / Sales | 5.2% | 4.1% | 6.9% | 5.0% | 2.7% | |
| SG&A / Sales | 9.0% | 8.4% | 7.3% | 6.1% | 7.5% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.5% | 0.6% | 0.7% | 0.5% | 0.6% | |
| Intangibles / Total assets | 8.3% | 9.1% | 9.7% | 8.1% | 1.6% | |
| Days sales outstanding | 56d | 53d | 51d | 56d | 60d | |
| Days payables outstanding | 20d | 19d | 19d | 22d | 29d | |
| Operating cycle | 108d | 107d | 106d | 116d | 121d | |
| Cash conversion cycle | 88d | 88d | 87d | 94d | 91d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+5.0%EV / Sales ▲+6.1%EV / EBITDA ▲+129.3%EV / Op. cash flow ▲+2.279Earnings yield ▼-0.065Graham number ▼-34.147
Profitability
Return on equity ▼-0.093Return on assets ▼-0.059Return on invested capital ▼-0.019Return on capital employed ▼-0.028Operating ROA ▼-0.029Income quality ▲+6.593Tax burden ▲+0.023
Efficiency
Days sales outstanding ▲+2.873Days payables outstanding ▲+0.401Operating cycle ▲+0.704Cash conversion cycle ▲+0.303Capex / Sales ▲+0.011R&D / Sales n/a
Balance-sheet strength
Current ratio ▼-1.168Net debt / EBITDA ▲+0.365Working capital ▼-221913000.000Invested capital ▼-79114000.000Intangibles / Total assets ▼-0.008
Change over 5 years
Valuation
Market cap ▲+66.0%EV / Sales ▲+31.0%EV / EBITDA ▲+160.6%EV / Op. cash flow ▼-10.137Earnings yield ▼-0.092Graham number ▼-13.356
Profitability
Return on equity ▼-0.160Return on assets ▼-0.077Return on invested capital ▼-0.056Return on capital employed ▼-0.076Operating ROA ▼-0.063Income quality ▲+7.893Tax burden ▲+0.014
Efficiency
Days sales outstanding ▼-3.720Days payables outstanding ▼-9.368Operating cycle ▼-12.587Cash conversion cycle ▼-3.219Capex / Sales ▲+0.024R&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.015Net debt / EBITDA ▼-0.050Working capital ▲+479650000.000Invested capital ▲+2177723000.000Intangibles / Total assets ▲+0.067
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-08-18 Commercial Metals Company: Working On Its Foundation Commercial Metals Company is executing a strategy focused on higher-margin, less capital-intensive operations following $2.5 billion in transformative M&A. Commercial Metals targets $1.65–$1.80 billion core EBITDA and $11B revenue by 2029, aiming to nearly double free cash flow per share. Leverage remains in the low 2s as Commercial Metals prioritizes EBITDA growth and shareholder returns via increased buybacks over rapid debt reduction.
- 2026-08-11 AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics
- 2026-08-11 Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological
- 2026-08-09 Amundi Purchases 11,065 Shares of Commercial Metals Company $CMC Amundi lifted its holdings in Commercial Metals Company (NYSE: CMC) by 118.0% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 20,443 shares of the basic materials company''s stock after purchasing an additional 11,065 shares during the quarter. Amundi''s holdings in Commercial
- 2026-08-08 Commercial Metals Company (CMC) Analyst/Investor Day Transcript Commercial Metals Company (CMC) Analyst/Investor Day Transcript
- 2026-08-05 Commercial Metals Targets $1.8B EBITDA, Expands Construction Solutions Strategy Commercial Metals NYSE: CMC used its 2026 Investor Day to outline a strategy centered on expanding its early-stage construction offerings, improving operating performance and generating higher cash flow and returns by fiscal 2029.
- 2026-08-05 CMC Highlights Position as a Leading, Early-Stage Construction Solutions Provider and Unveils Long-Term Financial Targets at 2026 Investor Day IRVING, Texas, Aug. 5, 2026 /PRNewswire/ -- CMC (NYSE: CMC) (the "Company") today will host its 2026 Investor Day in New York City, where members of the Company''s leadership team will outline CMC''s strategic vision, growth opportunities, capital allocation framework, and long-term financial targets. "Over the last several years, we have taken deliberate steps to transform CMC into an industry-leading provider of solutions across the early-stage construction ecosystem.
- 2026-08-05 CMC Announces $600 Million Increase in Share Repurchase Program Authorization IRVING, Texas, Aug. 5, 2026 /PRNewswire/ -- CMC (NYSE: CMC) (the "Company" or "CMC") today announced that its Board of Directors has authorized a $600.0 million increase in the Company''s existing common stock repurchase program, bringing the total current capacity of the program to approximately $717.0 million. Approximately $733.0 million of the Company''s common stock has been repurchased under the existing program since its authorization in October 2021.
- 2026-08-04 Commercial Metals Company (NYSE:CMC) Given Consensus Rating of “Moderate Buy” by Brokerages Commercial Metals Company (NYSE: CMC - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the fifteen research firms that are presently covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong
- 2026-08-03 Achieve Life Sciences Appoints Ronald Dadino and Gloria Cosgrove to Lead CMC, Supply Chain, and Quality SEATTLE and VANCOUVER, British Columbia, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced the appointments of Ronald Dadino as Senior Vice President, Chemistry, Manufacturing and Controls (CMC) and Supply Chain, and Gloria Cosgrove as Senior Vice President, Quality. Both executives bring decades of leadership across pharmaceutical manufacturing, supply chain, and quality.